Rheos Medicines: Sanjay Keswani
Industry veteran, Sanjay Keswani has taken up the position of CEO of Rheos Medicines. The biopharma company is looking to use immune cell metabolism to develop medicines able to treat immune-mediated diseases and cancers.
Keswani joins as CEO after having built up a solid biopharma background that included roles at Roche, BMS, Eli Lilly and Amgen. The most recent role he held was at Roche, where he was SVP and global head of R&D for neuroscience, ophthalmology and rare diseases. Keswani will replace interim CEO, Abbie Celniker.
The main focus of his expertise is within the neurosciences, which he specialised in at BMS, Eli Lilly and Amgen – prior to his work in the pharma industry, he held the position of assistant professor of neurology at Johns Hopkins University.
Keswani said of his new role: “There is an immense opportunity to change the therapeutic paradigm for treating diseases that involve the immune system, and Rheos is ideally positioned to set a new standard by targeting the underlying cellular metabolism of immune cells to treat a wide range of diseases.”
